Physician profile
Dora Afrahim
NPI 1205488475
$984.48
in general payments reported to CMS, 2019-2025
15 companies · $25.89 in 2025
The $25.89 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $50.23 · 2024: $21.46 · 2025: $25.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $136.97 | 2021 | |
| Csl Behring | $127.17 | 2021 | |
| Alexion Pharmaceuticals, INC. | $120.90 | 2021 | |
| Glaxosmithkline, LLC. | $89.44 | 2021-2024 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $76.25 | 2021 | |
| Pfizer INC. | $71.18 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $59.77 | 2021 | |
| Optinose US, INC. | $56.69 | 2021 | |
| Kaleo, INC. | $50.50 | 2021 | |
| Genzyme Corporation | $49.52 | 2021 | |
| Amgen INC. | $49.02 | 2021-2025 | Tezspire |
| Ge Healthcare | $32.44 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.03 | 2021 | |
| Biocryst US Sales Co., LLC | $22.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dora Afrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.